Medical Director: Precision Medicine
Ryan Nelson, PharmD
Medical Director, Precision Medicine
Adjunct Professor, University of Utah School of Medicine
Applied precision medicine
Somatic pharmacogenomics
Germline pharmacogenomics
Doctorate Degree—Pharmacy, University of Utah College of Pharmacy
Fellowship—Personalized Cancer Medicine, Moffitt Cancer Center
Memberships/Affiliations
American Society of Health-System Pharmacists
Clinical Pharmacogenetics Implementation Consortium
Clinical utility and value of pharmacogenomics
Gene-drug pair assessment for future implementation
Patient adherence to pharmacotherapy
Nelson RS, et al. UGT1A1 guided dancer therapy: review of the evidence and considerations for clinical implementation. Cancers (Basel). 2021;13(7):1566.
Mason NT, et al.Budget impact of adaptive abiraterone therapy for castration-resistant prostate cancer. Am Health Drug Benefits. 2021;14(1):15-20.
Nelson RS, et al. Prioritization of therapy options for apatient with high tumor mutation burden and microsatellite instability but no clinical benefit from immunotherapy. JCO Precis Oncol. 2019;3:PO.19.00197.
Hunter AM, et al. CSF3R mutations are exceedingly rare genetic events associated with inferior survival and sensitivity to ruxolitinib across myeloid malignancies. Myeloid Malignancies. Blood. 2019;134(Supplement_1):4167.
Stenehjem DD, et al. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. 2019;29(6):626-634.
Wang Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a cross-sectional study. Chemotherapy. 2019;64(4):197-204.
Kim K, et al. Clinical utility of pharmacogenetic testing and a clinical decision support tool to enhance the identification of drug therapy problems through medication therapy management in polypharmacy patients. J Manag Care Spec Pharm. 2018;24(12):1250-1259.
Zhang M, et al. Prevalence and risk factors of immunosuppressant nonadherence in heart transplant recipients: a single-center cross-sectional study. Patient Prefer Adherence. 2019;13:2185-2193.
Au TH, et al. Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: preliminary results from multi-site study in the U.S. Palliative and Supportive Care in Oncology Symposium. San Diego, CA. Nov 16-17, 2018. Journal of Clinical Oncology 36, no. 34_suppl. (Dec 2018) 16-16.
Au T, et al. Development of a novel burden survey for caregivers of glioblastoma multiforme (GBM) patients. Neuro Oncol. 2017;19(Suppl 6):vi110.
Abstracts/Posters
J Eli, et al. MetaCensus: a blockchain meta-analysis database to improve scientific consensus and clinical decision support in pharmacogenomics. Abstract 131019, 2022 CPIC-PGRN meeting.
Nelson RS, et al. Processes for integrating a pharmacogenomics panel into patient care at an academic cancer research hospital. Poster presentation at the Clinical Pharmacogenetics Implementation Consortium (CPIC) open meeting, Memphis TN, June 6-7, 2019.